BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc, Company announcement, 22 May 2023 4:00 p.m.
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc (“BBS” or the "Company") has received a request by Riverfort Global Opportunities PCC Ltd to convert a proportion of EUR 25,000 of the convertible notes into Company shares at a conversion price of EUR 0.755460 per share. The conversion will be done pursuant to the terms and conditions of the financing arrangement between the Company and Riverfort Global Opportunities PCC Ltd announced on 31 March 2023.
The Conversion price according to the terms and conditions is “90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice“.
The conversion shall be executed by transferring a total of 33,092 of treasury shares to Riverfort Global Opportunities PCC Ltd. After the transfer, the Company will hold a total of 392,128 treasury shares in its possession.
BBS announced on 31 March 2023 it had renewed an investment agreement for a capital facility with RiverFort Global Opportunities PCC Ltd. The investment agreement strengthened the Company's working capital position and supported the Company's objective of submitting the CE marking application to the authorities.
For more information, please contact:
Ilkka Kangasniemi, CEO,
+358 40 7080307,
ilkka.kangasniemi@bbs-artebone.fi
Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.s
BBS in brief
BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our developed product, ARTEBONE®, is in the final stages of product development, and we are seeking the CE marking to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ 20 people.
BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.
More information: www.bbs-artebone.fi
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ress Life Investment A/S announces capital increase30.5.2023 15:54:15 CEST | Press release
Ress Life Investments A/S Nybrogade 12, 1203 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 30 May 2023 Corporate Announcement 19/2023 Ress Life Investments A/S announces capital increase. The Board of Directors in Ress Life Investments A/S has today resolved to utilise its authorisation in article 4.8 of the articles of association to increase the company's share capital with nominally EUR 625,000 by issuance of 1,250 new shares with a nominal value of EUR 500 each at a price of EUR 2184.16 per share of EUR 500 without pre-emption rights for the company's existing shareholders. After the capital increase, the registered share capital of the company is EUR 84,760,500 divided into 169,521 shares of EUR 500 nominal value each. Each share of nominal EUR 500 carries one vote at general meetings in Ress Life Investments A/S. The new shares will be admitted for trading and official listing on NASDAQ Copenhagen A/S under the same ISIN code as the
Mandatory Notification of Trade30.5.2023 15:43:14 CEST | Press release
Please refer to the attached forms of notification of transaction by primary insiders under the DNO ASA Employee Synthetic Share Program. This notification has been submitted pursuant to the Norwegian Securities Trading Act § 5-12 and MAR Article 19 no. 3. Attachments Form of Notification Cash Settlement Geir Arne Skau 26 05 2023Form of Notification Cash Settlement Haakon Sandborg 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Chris Spencer 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Geir Arne Skau 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Haakon Sandborg 26 05 2023Form of Notification Cash Settlement Chris Spencer 26 05 2023
Correction: Avance Gas Holding Ltd: Key information relating to the dividend for the first quarter 202330.5.2023 15:30:30 CEST | Press release
Bermuda, May 30 2023 Please note that the record date has been included to the below key information relating to dividend for the first quarter 2023. Key information relating to the dividend to be paid by Avance Gas Holding Ltd. for the first quarter 2023: Dividend amount: $0.50 Declared currency: USD Last day including right: June 6, 2023 Ex-date: June 7, 2023 Record date: June 8, 2023 Payment date: June 14, 2023 Date of Approval: May 29, 2023 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control30.5.2023 15:30:00 CEST | Press release
Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control Proposal to appoint Jonathan Milner Executive Chairman of the Board Proposal to remove Peter Allen, Michael Baldock, and Sally Crawford as Directors of the Company ExecutiveChairman Milner intends torestore Abcam to the valuation it deserves CAMBRIDGE, England, 30May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.3% of the Company, announced today that he has formally requisitioned the Board of Directors to convene an extraordinary general meeting of shareholders (“EGM”) to reverse a period of sustained financial and operational underperformance by providing more effective Board level leadership for the Company. The EGM will enable shareholders to vote on the following proposals: The removal of Peter Allen, Michael Baldock, and Sally Crawford from office as Directors of the
PHARMANOVIA ENTERS NEW CHEMICAL ENTITY LICENSING AGREEMENT WITH STEALTH BIOTHERAPEUTICS TO MARKET AND FURTHER DEVELOP A POTENTIAL NOVEL TREATMENT FOR BARTH SYNDROME30.5.2023 15:25:24 CEST | Press release
Basildon, UK, May 30, 2023 (GLOBE NEWSWIRE) -- PRESS RELEASE - FOR BUSINESS & TRADE MEDIA ONLY THE AGREEMENT COVERS RIGHTS FOR ELAMIPRETIDE FOR BARTH SYNDROME IN THE EU, NORWAY, SWITZERLAND, UK, ICELAND, AND MIDDLE EAST & NORTH AFRICA (MENA) TERRITORIESTHERE ARE NO CURRENT APPROVED TREATMENTS FOR BARTH SYNDROMETHIRD NEW CHEMICAL ENTITY DEAL FOR PHARMANOVIA, EXPANDING PORTFOLIO IN CARDIOLOGY AND RARE DISEASES Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its cardiology portfolio through a new licensing agreement with US-based biopharmaceutical company, Stealth BioTherapeutics Inc. The agreement gives Pharmanovia the licensing rights to elamipretide for Barth syndrome in Europe and MENA. This is a significant milestone as ongoing studies indicate that elamipretide has the potential to improve the quality of life for people with Barth syndrom